Download PDF
CC BY 4.0 · Eur J Dent 2022; 16(02): 266-273
DOI: 10.1055/s-0041-1736330
Review Article

Cyberknife Radiosurgery for the Treatment of Head and Neck Cancer: A Systematic Review

Cristalle Soman 
1   Department of Oral Medicine and Maxillofacial Radiology, Riyadh Elm University, Riyadh, Saudi Arabia
,
Shahad Ramzi Mohammed Alghamdi
2   College of Dentistry, Riyadh Elm University, Riyadh, Saudi Arabia
,
Faisal Nahar M. Alazemi
3   College of Dentistry, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
,
Abdulaziz Ahmad Abdullah Alghamdi
3   College of Dentistry, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Cyberknife radiosurgery is a frameless stereotactic robotic radiosurgery which has shown to deliver better treatment outcomes in the treatment of advanced head and neck (H&N) carcinomas, especially in previously irradiated and recurrent cases. The aim of the study was to perform a systematic review of the available data on the outcomes of Cyberknife radiosurgery for treatment of head and neck cancer and to evaluate its collective outcomes. This systematic review was registered with the university with the registration no. FRP/2019/63 and was approved by the Institutional Review Board (RC/IRB/2019/132). Literature search was performed in the following: PubMed, Science direct, SciELO, MyScienceWork, Microsoft Academ EMBASE, Directory of Open Access Journals, and Cochrane databases with the keywords “Cyberknife,” “oral cancer,” “oropharyngeal cancer,” and “head and neck cancer” and data was extracted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The records identified were 147 manuscripts. Excluded articles included 5 duplicate articles, 33 abstracts, 101 full text articles due to being off-topic, case reports, review, non-English, 1 survey, and 2 other articles containing data extracted from a main study which was already included. A total of 5 articles were evaluated for qualitative synthesis. The mean dose of Cyberknife radiosurgery delivered for previously irradiated recurrent H&N carcinoma patients was 34.57 Gy, with a mean sample size of 5 studied during the period of 2000 to 2016. The available evidence from the systematic review indicates that Cyberknife can be an efficacious treatment option for recurrent previously irradiated H&N carcinoma, especially for nonresectable tumors. There is paucity of homogenous data and studies in this arena; hence, meta-analysis could not be performed. Further standardized studies are essential, especially where the treatment of H&N carcinoma is considered.

Keywords

cyberknife radiosurgery - oropharyngeal neoplasms - treatment outcomes of cyberknife - cyberknife radiotherapy - head and neck neoplasm - targeted radiation therapy - stereotactic radiotherapy - robotic radiosurgery

Note

The manuscript was available as a “preprint” in SSRN, formerly known as Social Science Research Network, and Lancet oncology which is both a repository for preprints and international journal devoted to the rapid dissemination of scholarly research.


Authors' Contributions

C.S., S.R.M.A., F.N.M.A., and A.A.A.A. were part of the project management group. C.S. contributed to conception, design, data acquisition and interpretation as well as drafting and critically revising the manuscript. S.R.M.A. contributed to data acquisition and analysis and critically revised the manuscript. F.N.M.A. contributed to data acquisition and analysis and critically revised the manuscript. A.A.A.A. contributed to data acquisition and analysis and critically revised the manuscript. All authors gave their final approval and agreed to be accountable for all aspects of the work, ensuring integrity and accuracy of the study.




Publication History

Article published online:
10 December 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kurup G. CyberKnife: a new paradigm in radiotherapy. J Med Phys 2010; 35 (02) 63-64
    CrossrefPubMedGoogle Scholar
  • 2 Adler JR, Murphy MJ, Chang SD, Hancock SL. Image-guided robotic radiosurgery. Neurosurgery 1999; 44 (06) 1299-1306 , discussion 1306–1307
    PubMedGoogle Scholar
  • 3 Bonomo P, Cipressi S, Iermano C. et al. Salvage stereotactic re-irradiation with CyberKnife for locally recurrent head and neck cancer: a single center experience. Tumori 2014; 100 (03) 278-283
    CrossrefPubMedGoogle Scholar
  • 4 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700
    Google Scholar
  • 5 Yamazaki H, Demizu Y, Okimoto T. et al. Comparison of re-irradiation outcomes for charged particle radiotherapy and robotic stereotactic radiotherapy using CyberKnife for recurrent head and neck cancers: a multi-institutional matched-cohort analysis. Anticancer Res 2016; 36 (10) 5507-5514
    CrossrefPubMedGoogle Scholar
  • 6 Stanisce L, Koshkareva Y, Xu Q. et al. Stereotactic body radiotherapy treatment for recurrent, previously irradiated head and neck cancer. Technol Cancer Res Treat 2018; 17: 1533033818780086
    Google Scholar
  • 7 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedGoogle Scholar
  • 8 Higgins JP, Altman DG, Gøtzsche PC. et al; Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    Google Scholar
  • 9 Higgins J.P., Altman D.G.. Chapter 8: Assessing risk of bias in included studies. In: Higgins J.P., Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series. Wiley-Blackwell; Hoboken, NJ2008: 187-241
    Google Scholar
  • 10 Langer CJ, Harris J, Horwitz EM. et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007; 25 (30) 4800-4805
    CrossrefPubMedGoogle Scholar
  • 11 Spencer SA, Harris J, Wheeler RH. et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008; 30 (03) 281-288
    CrossrefPubMedGoogle Scholar
  • 12 De Crevoisier R, Bourhis J, Domenge C. et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998; 16 (11) 3556-3562
    CrossrefPubMedGoogle Scholar
  • 13 Ohizumi Y, Tamai Y, Imamiya S, Akiba T. Prognostic factors of reirradiation for recurrent head and neck cancer. Am J Clin Oncol 2002; 25 (04) 408-413
    CrossrefPubMedGoogle Scholar
  • 14 Salama JK, Vokes EE, Chmura SJ. et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64 (02) 382-391
    CrossrefPubMedGoogle Scholar
  • 15 Kharofa J, Choong N, Wang D. et al. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. Int J Radiat Oncol Biol Phys 2012; 83 (02) 690-695
    CrossrefPubMedGoogle Scholar
  • 16 Mead PH. Surgery or radiotherapy for tonsil cancer?. Cancer 1963; 16: 195-198
    CrossrefPubMedGoogle Scholar
  • 17 Langlands AO. Radiation therapy in the treatment of cancer: the past, the present, and the future. Aust N Z J Surg 1982; 52 (04) 331-335
    CrossrefPubMedGoogle Scholar
  • 18 Montana GS, Hellman S, Von Essen CF, Kligerman MM. Carcinoma of the tongue and floor of the mouth. Results of radical radiotherapy. Cancer 1969; 23 (06) 1284-1289
    CrossrefPubMedGoogle Scholar
  • 19 Perez CA, Holtz S, Ogura JH, Dedo HH, Powers WE. Radiation therapy of early carcinoma of the true vocal cords. Cancer 1968; 21 (04) 764-771
    CrossrefPubMedGoogle Scholar
  • 20 Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer 2008; 113 (7, Suppl) 1911-1932
    CrossrefPubMedGoogle Scholar
  • 21 Kaplan MJ, Johns ME, Clark DA, Cantrell RW. Glottic carcinoma. The roles of surgery and irradiation. Cancer 1984; 53 (12) 2641-2648
    CrossrefPubMedGoogle Scholar
  • 22 Mendenhall WM, Morris CG, Amdur RJ. et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol 2006; 29 (03) 290-297
    CrossrefPubMedGoogle Scholar
  • 23 Nakamura K, Shioyama Y, Kawashima M. et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65 (04) 1045-1050
    CrossrefPubMedGoogle Scholar
  • 24 Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24 (17) 2618-2623
    CrossrefPubMedGoogle Scholar
  • 25 Lee N, Puri DR, Blanco AI, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 2007; 29 (04) 387-400
    CrossrefPubMedGoogle Scholar
  • 26 Schwartz DL, Ford EC, Rajendran J. et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 2005; 27 (06) 478-487
    CrossrefPubMedGoogle Scholar
  • 27 Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer 2005; 104 (06) 1296-1303
    CrossrefPubMedGoogle Scholar
  • 28 Ryu S, Khan M, Yin FF. et al. Image-guided radiosurgery of head and neck cancers. Otolaryngol Head Neck Surg 2004; 130 (06) 690-697
    CrossrefPubMedGoogle Scholar
  • 29 Voynov G, Heron DE, Burton S. et al. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technol Cancer Res Treat 2006; 5 (05) 529-535
    CrossrefPubMedGoogle Scholar
  • 30 Adler JR, Pham CJ, Chang SD, Rodas RA. Image-guided Robotic Radiosurgery: The CyberKnife. Perspective in Neuroscience. Bloomington (IL): Central Illinois Neuroscience Foundation; 2003
    Google Scholar
  • 31 Srivastava R, Jyoti B, Gupta M, Singh N. CyberKnife: The cutting edge technology in precision surgery. SRM J Res Dent Sci 2015; 6: 106-115
    CrossrefGoogle Scholar
  • 32 Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer Jr CR. The CyberKnife Robotic Radiosurgery System in 2010. Technol Cancer Res Treat 2010; 9 (05) 433-452
    CrossrefPubMedGoogle Scholar
  • 33 Mahboubi H, Sahyouni R, Moshtaghi O. et al. CyberKnife for treatment of vestibular schwannoma: a meta-analysis. Otolaryngol Head Neck Surg 2017; 157 (01) 7-15
    CrossrefPubMedGoogle Scholar
  • 34 Yamazaki H, Ogita M, Himei K. et al. Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer. J Radiat Res (Tokyo) 2016; 57 (03) 288-293
    CrossrefPubMedGoogle Scholar
  • 35 Rwigema JC, Heron DE, Ferris RL. et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol 2011; 34 (04) 372-379
    CrossrefPubMedGoogle Scholar
  • 36 Kawaguchi K, Sato K, Horie A. et al. Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma. Radiat Oncol 2010; 5: 51
    CrossrefPubMedGoogle Scholar
  • 37 Salins N, Omkarappa LS. Type 2 (impending) carotid blow out syndrome. Indian J Palliat Care 2013; 19 (02) 119
    CrossrefPubMedGoogle Scholar
  • 38 Jacobi C, Gahleitner C, Bier H, Knopf A. Chemoradiation and local recurrence of head and neck squamous cell carcinoma and the risk of carotid artery blowout. Head Neck 2019; 41 (09) 3073-3079
    CrossrefPubMedGoogle Scholar
  • 39 Gahleitner C, Hofauer B, Storck K, Knopf A. Outcome of carotid and subclavian blowout syndrome in patients with pharynx- and larynx carcinoma passing a standardized multidisciplinary treatment. Acta Otolaryngol 2018; 138 (05) 507-512
    CrossrefPubMedGoogle Scholar
  • 40 Chiesa Estomba CM, Betances Reinoso FA, Osorio Velasquez A, Castro Macia O, Gonzalez Cortés MJ, Araujo Nores J. Carotid blowout syndrome in patients treated by larynx cancer. Rev Bras Otorrinolaringol (Engl Ed) 2017; 83 (06) 653-658
    Google Scholar
  • 41 Alsharif MT, Alsharif AT, Krsoum MA. et al. Trend analysis of head and neck neoplasms between 2012-2018 in patients residing in Al-Madinah, Saudi Arabia: a retrospective study. Eur J Dent 2021; 15 (03) 509-514
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Miranda-Filho A, Bray F. Global patterns and trends in cancers of the lip, tongue and mouth. Oral Oncol 2020; 102: 104551
    CrossrefPubMedGoogle Scholar
  • 43 Grafton-Clarke C, Chen KW, Wilcock J. Diagnosis and referral delays in primary care for oral squamous cell cancer: a systematic review. Br J Gen Pract 2019; 69 (679) e112-e126
    CrossrefPubMedGoogle Scholar
  • 44 Lopez-Cedrún JL, Otero-Rico A, Vázquez-Mahía I. et al. Association between hospital interval and survival in patients with oral cancer: A waiting time paradox. PLoS One 2019; 14 (10) e0224067
    CrossrefPubMedGoogle Scholar
  • 45 Hassan SS, Attia MA, Attia AM, Nofal RA, Fathi A. Distribution of cytokeratin 17 in the parenchymal elements of rat's submandibular glands subjected to fractionated radiotherapy. Eur J Dent 2020; 14 (03) 440-447
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Rouers M, Bornert F, Truntzer P. et al. Ability to propose optimal prosthetic rehabilitation can be improved by discussion between the dentist and radiation oncologist regarding upstream dosimetry. Eur J Dent 2019; 13 (01) 88-94
    Article in Thieme ConnectPubMedGoogle Scholar